SCHEMBL4280104

SCHEMBL4280104

O=C(O)CC1CN2CCC1CC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 1/20 0.41
▸ CHRM2 P08172 4/20 0.40
▸ SLC6A12 P48065 3/20 0.40
▸ SLC6A11 P48066 3/20 0.40
▸ SLC6A13 Q9NSD5 3/20 0.40
▸ CYP2D6 P10635 2/20 0.40
▸ CHRM1 P11229 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ CHRM3 P20309 2/20 0.38
▸ EGFR P00533 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ ADRA2A P08913 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ DRD2 P14416 1/20 0.38
▸ ADRA2B P18089 1/20 0.38
▸ ADRA2C P18825 1/20 0.38
▸ DRD1 P21728 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21063808 1.00 CHRNA7 (0.41) CHRNA7CHRM2SLC6A12SLC6A11SLC6A13
SCHEMBL21063738 1.00 CHRNA7 (0.41) CHRNA7CHRM2SLC6A12SLC6A11SLC6A13
Hydrochloric Acid SCHEMBL23406281 0.98 SLC6A12 (0.42) CHRNA7CHRM2SLC6A12SLC6A11SLC6A13
Hydrochloric Acid SCHEMBL2422058 0.98 SLC6A12 (0.42) CHRNA7CHRM2SLC6A12SLC6A11SLC6A13
SCHEMBL29271818 0.98 CHRNA7 (0.40) CHRNA7CHRM2SLC6A12SLC6A11SLC6A13
Hydrochloric Acid SCHEMBL26105242 0.98 SLC6A12 (0.42) CHRNA7CHRM2SLC6A12SLC6A11SLC6A13
SCHEMBL21095889 0.90 SLC6A12 (0.39) CHRNA7CHRM2SLC6A12SLC6A11SLC6A13
SCHEMBL21095754 0.90 SLC6A12 (0.39) CHRNA7CHRM2SLC6A12SLC6A11SLC6A13
SCHEMBL660508 0.82 CHRNA7 (0.45) CHRNA7CHRM2CYP2D6CHRM1MEN1
SCHEMBL6650217 0.82 CHRNA7 (0.40) CHRNA7CHRM2CYP2D6CHRM1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113444005-A Method for synthesizing novel glutaric acid compound from diaryl substituted non-activated olefin 四川大学 2021-09-28 — — CN claimed
EP-4559918-A2 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2025-05-28 — — EP disclosed
EP-3673906-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2025-05-14 — — EP disclosed
CN-114588156-B Ophthalmic preparation and application thereof in treating presbyopia 温州医科大学附属眼视光医院 2024-06-11 — — CN disclosed
EP-3724188-B1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2023-06-07 — — EP disclosed
US-20210163471-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS 2021-06-03 — — US disclosed
CN-107080747-B Glucosylceramide synthase inhibitors 建新公司 2021-02-26 — — CN disclosed
EP-3724188-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME Arkuda Therapeutics (US) 2020-10-21 — — EP disclosed
EP-3673906-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2020-07-01 — — EP disclosed
US-20200048266-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2020-02-13 — — US disclosed
EP-1487835-B1 AMIDES OF ACETIC AND PROPIONIC ACIDS BAYER HEALTHCARE AG (DE) 2006-09-20 — — EP disclosed
US-20050154045-A1 Aza-bicyclic n-biarylamides with affinity for the alpha-7 nicotinic acetylcholine receptor BAYER HEALTHCARE AG (DE) 2005-07-14 — — US disclosed
EP-1487834-A1 AZA-BICYCLIC N-BIARYLAMIDES WITH AFFINITY FOR THE ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR Bayer Aktiengesellschaft (DE) 2004-12-22 — — EP disclosed
EP-1487835-A1 AMIDES OF ACETIC AND PROPIONIC ACIDS Bayer Aktiengesellschaft (DE) 2004-12-22 — — EP disclosed
WO-2003078431-A1 AZA-BICYCLIC N-BIARYLAMIDES WITH AFFINITY FOR THE ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR BAYER HEALTHCARE AG (DE) 2003-09-25 — — WO disclosed
WO-2003078430-A1 AMIDES OF ACETIC AND PROPIONIC ACIDS BAYER HEALTHCARE AG (DE) 2003-09-25 — — WO disclosed
EP-0934316-B1 AZABICYCLIC CARBAMOYLOXY MUTILIN DERIVATIVES FOR ANTIBACTERIAL USE SMITHKLINE BEECHAM PLC (GB) 2002-10-16 — — EP disclosed
US-6121281-A Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use SMITHKLINE BEECHAM P.L.C. (GB) 2000-09-19 — — US disclosed
EP-0934316-A1 AZABICYCLIC CARBAMOYLOXY MUTILIN DERIVATIVES FOR ANTIBACTERIAL USE SMITHKLINE BEECHAM PLC (GB) 1999-08-11 — — EP disclosed
WO-1998005659-A1 AZABICYCLIC CARBAMOYLOXY MUTILIN DERIVATIVES FOR ANTIBACTERIAL USE SMITHKLINE BEECHAM PLC (GB) 1998-02-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048266-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA CHRNA7 4678/4885CHRM2 4876/4885SLC6A12 2616/4885
US-20210163471-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME GRN, PRNP, PSEN1 CHRNA7 2271/4885CHRM2 4042/4885SLC6A12 3989/4885
US-20050154045-A1 Aza-bicyclic n-biarylamides with affinity for the alpha-7 nicotinic acetylcholine receptor CHRNA7, CHRNA5, CHRNA2 CHRNA7 1/4885CHRM2 31/4885SLC6A12 2074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback